Angelman Syndrome Natural History Study-FAST UK

Angelman Syndrome Clinical Trial

Official title:

A Monocentric, Prospective, Longitudinal and Observational Natural History Study for Patients With Angelman Syndrome in the United Kingdom: Natural History - Foundation for Angelman Syndrome Therapeutics (FAST) United Kingdom (UK)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05100810
• Other study ID #: PID15397
• Status: Recruiting
• Start date: November 1, 2021
• Est. completion date: December 31, 2024

Study information

• Verified date: November 2023
• Source: University of Oxford
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this study is to conduct a prospective, longitudinal assessment of the natural clinical progression of Angelman syndrome (AS) in children and adults. This will be performed by acquiring baseline measurements, and developing effective outcome measures and diagnostic tools for the syndrome, to prepare the healthcare system for forthcoming clinical trials.

Description:

This study is being conducted in anticipation of several candidate therapies which are approaching clinical readiness for Angelman syndrome. This study will comprehensively evaluate the natural clinical progression of the disease using scales and questionnaires for the assessment of motor function and global development, motor measuring devices (ActiMyo), and by collecting sleep and seizure diaries. In addition, proteomic analysis and electroencephalography (EEG) recordings will be collected to identify biomarkers which will indicate improvements in disease outcome following treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

For the candidate participants affected by AS:

• Genetically confirmed diagnosis of AS
• 0-99 years
• Male or Female
• Obtained consent forms and/or record of consultation by the carers. In this study, the two primary carers for each participant diagnosed with AS will be also

considered participants. Carers will have to meet the following inclusion criteria:

• Male or Female
• >18 years
• Legal carer of the patient diagnosed with AS
• Willingness to follow study procedures, as assessed by the research team
• Willingness to sign the consent form
• Ability to understand all the information regarding the study, as assessed by the research team

Exclusion Criteria:

• The participant affected by AS may not enter the study if there is any comorbidity (*) that could potentially affect the results of the study. This will be subject to the clinical judgement of the Chief Investigator (CI) and/or the Principal Investigator (PI). Participants of ongoing (interventional) clinical trials that assess the efficacy of potential treatments will be excluded as assessments need to be done on the basis that represent the natural progression of AS. (*) This includes any confirmed chronic or acute condition or disease affecting any system(s), which could interfere with the results of the study and/or the compliance with the study procedures.

Related Conditions & MeSH terms

• Angelman Syndrome
• Syndrome

Intervention

Other:
• Natural History Study
Longitudinal assessment of disease progression of Angelman syndrome in patients

Locations

Country	Name	City	State
United Kingdom	University of Oxford	Oxford	Oxon

Sponsors (3)

Lead Sponsor	Collaborator
University of Oxford	Foundation for Angelman Syndrome Therapeutics UK, Hoffmann-La Roche

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	DNA biobank	Blood sample collection and DNA extraction and storage	2 years and 1 month
Primary	Collection of relevant medical data (retrospective and prospective)	Collection of demographic data, Angelman Syndrome-related medical history, past medical and surgical history, current medication, history of immunisations and family medical history.	2 years 1 month
Primary	Neurological assessment scale	Hammersmith Infant Neurological Examination (HINE) (0-2 years ONLY). Maximum global score of 78. Higher scores indicate a higher degree of neurological performance.	2 years 1 month
Primary	Clinical Scale	Clinical Global Impressions Scale - Angelman Syndrome version (CGI-SAS). Scales whereby practitioner rates from 1 to 7 the overall improvement/deterioration of the participant affected by Angelman Syndrome. One is improved and 7 denotes deterioration.	2 years 1 month
Primary	Clinical Scale	Caregiver-reported Angelman Syndrome Scale (CASS). Scales whereby the carer rates from 1 to 7 the overall improvement/deterioration of the participant affected to by Angelman Syndrome. One is improved and 7 denotes deterioration.	2 years 1 month
Secondary	Movement monitoring using wearable device	Continuous movement monitoring using actimetry ActiMyo® in uncontrolled environment (i.e., home)	2 years 1 month
Secondary	Gross motor milestones	World Health Organisation (WHO) Motor Milestones. Scale of 6 gross motor milestones. Lower scores denotes worse motor function.	2 years 1 month
Secondary	Global development assessment scale	Bayley Scales of Infant and Toddler Development - 4 (BSID-4) for Developmental delays. Scale is divided into five domains, which are further divided into subdomains. The first step is to calculate the starting point by beginning with the items that are age appropriate. The starting point is validated if three consecutive items are achieved. If the participant affected by Angelman Syndrome does not achieve three consecutive items in a row at the age-appropriated starting point, the evaluator must go backwards to the lower age-starting point until the participant affected by Angelman Syndrome achieves three items in a row. The assessment stops once five items in a row are not achieved.	2 years 1 month
Secondary	Global development assessment scale	Vineland Adaptive Behaviour Scales-III (VABS-III). Scale composed of two main domains, which are subdivided into several subdomains. Lower score indicates worse cognitive functioning.	2 years 1 month
Secondary	Aberrant behaviour assessment	Aberrant Behaviour Checklist-Community (ABC-C). This scale comprises 58 items and is divided into five subdomains. The ABC-C is designed on a four-point scale with the lowest score representing less-affected patients while the highest score represents the severest patients.	2 years 1 month
Secondary	Communication assessment	Observed Reported Communication Assessment (ORCA) Tool. Questionnaire designed to be completed by the patients' main carer and records patient communication.	2 years 1 month
Secondary	Motor function assessment	Functional Mobility Scale (FMS). Scale which rates the walking ability in three different walking distances, and these distances will be rated on a 6-point scale.	2 years 1 month
Secondary	Sleep and seizure activity	Sleep and seizure diaries with ready-made questionnaires	2 years 1 month
Secondary	Laboratory biomarkers for Angelman syndrome	Proteomic analysis of plasma samples to determine biomarkers of disease progression	2 years 1 month
Secondary	Electroencephalogram (EEG) activity recordings	Electroencephalogram (EEG) to record brain activity of Angelman Syndrome patients over a 24-hour period (e.g., sleep architecture, number and frequency of seizures, background epileptic activity, delta-rhythmicity)	24 hours
Secondary	Quality of Life questionnaires for families of Angelman syndrome patients	PedsQL-Family Module questionnaires. Questionnaire uses ranking system of 1-4 based on frequency.	2 years 1 month
Secondary	Quality of life assessment for individuals affected by Angelman syndrome	PedsQL-Core Module questionnaires. Questionnaire uses ranking system which depends on the age of patient.	2 years 1 month
Secondary	Health economics	Interview with Carer's	2 years and 1 month
Secondary	Clinical trial readiness	Demographic data collection and facilities preparation	2 years and 1 month